Related Experiment Video
Updated: Aug 9, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Myocardial surgical revascularization after streptokinase treatment for acute myocardial infarction
Insights
Intravenous streptokinase administration for myocardial infarction is as effective as intracoronary, offering earlier treatment and reduced costs. This thrombolytic therapy helps salvage heart muscle and improve patient outcomes.
Area of Science:
- Cardiology
- Thrombolytic Therapy
- Myocardial Infarction Management
Background:
- Myocardial infarction (MI) requires prompt treatment to restore coronary blood flow and preserve cardiac function.
- Streptokinase is a thrombolytic agent used in the management of acute MI.
- Evaluating different administration routes of streptokinase is crucial for optimizing patient outcomes.
Purpose of the Study:
- To compare the efficacy and safety of intracoronary versus intravenous streptokinase in patients with evolving myocardial infarction.
- To assess the impact of streptokinase administration on left ventricular function and myocardial salvage.
- To determine the long-term outcomes, including angina, rehabilitation, and mortality, associated with each treatment arm.
Main Methods:
- Eighty-six patients with evolving MI within 6 hours of symptom onset were randomized to receive either intracoronary or intravenous streptokinase.
- Coronary angiography was performed to assess artery patency and left ventricular function.
- Left ventricular hypokinesia and aneurysm formation were evaluated post-treatment.
- Patient outcomes, including freedom from angina, rehabilitation status (New York Heart Association Class I), and mortality, were tracked.
Main Results:
- No streptokinase-related complications were observed in either group.
- Time to treatment was significantly shorter for the intravenous group (3.2 +/- 1.5 hours) compared to the intracoronary group (4.4 +/- 1.6 hours).
- Both routes demonstrated effectiveness in salvaging myocardium, with similar rates of freedom from angina (69.5% intracoronary vs. 75% intravenous) and successful rehabilitation.
- Intravenous administration showed a trend towards better left ventricular function preservation and potentially lower rates of aneurysm formation.
Conclusions:
- Streptokinase-induced thrombolysis is effective in salvaging myocardium in patients with evolving myocardial infarction.
- The intravenous route of streptokinase administration appears to be as effective as the intracoronary route, with advantages of earlier administration, non-invasiveness, and lower cost.
- Earlier administration via the intravenous route may lead to increased myocardial salvage and improved overall patient outcomes.
Abstract:
Eighty-six patients admitted with evolving myocardial infarction within 6 hours of symptom onset were treated with streptokinase. Thirty-nine received intracoronary streptokinase, and 47 received intravenous streptokinase. There were no streptokinase-related complications. Twenty-three patients treated with intracoronary streptokinase and 28 patients receiving intravenous streptokinase underwent coronary artery bypass grafting. On admission, 16 patients receiving intracoronary streptokinase had electrocardiographic evidence of anterolateral evolving myocardial infarction and seven had evidence of inferior evolving myocardial infarction. Time from first symptom to intracoronary streptokinase was 4.4 +/- 1.6 hours. In seven patients, intracoronary streptokinase failed to open the obstructed coronary. All developed severe left ventricular hypokinesia in the area supplied by that coronary artery. In spite of recanalization, nine of 14 patients developed severe hypokinesia in the supplied area, and one an apical aneurysm. Four patients developed mild to moderate hypokinesia, and one had no left ventricular damage. On admission, 14 patients receiving intravenous streptokinase had electrocardiographic evidence of anterolateral evolving myocardial infarction and four had evidence of inferior evolving myocardial infarction. Time from first symptom to intravenous streptokinase was 3.2 +/- 1.5 hours. In seven patients, intravenous streptokinase failed to open the coronary, and all developed severe hypokinesia of the supplied area, with formation of apical left ventricular aneurysm in three. In 21 patients, intravenous streptokinase opened the artery. Eighteen angiographies performed 9.6 +/- 7.9 days after therapy showed a normal left ventricle in eight patients, moderate hypokinesia in seven, and severe hypokinesia in three. Time from first symptom to therapy was shorter in the patients receiving intravenous therapy (p less than 0.01). Coronary artery bypass grafting and four resections after left ventricular aneurysm were performed without operative death. Two patients receiving intracoronary therapy died in the hospital, and one died 2 months later from arrhythmias. Freedom from angina and rehabilitation (New York Heart Association Class I) were achieved in 69.5% of patients receiving intracoronary streptokinase and in 75% of patients receiving intravenous streptokinase. Thus streptokinase-induced thrombolysis salvages myocardium, and the intravenous route seems as effective as the intracoronary. Advantages of the former are earlier administration that might increase myocardial salvage, no invasive procedure, and lesser cost.
More Related Videos
07:50Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
05:25Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
Related Concept Videos
Myocarditis III: Medical Management
Acute Coronary Syndrome I: Introduction